New from BioWorld, Innovations in Biotechnology 2010: Visionary Start-Ups and Revolutionary Science, offers a landmark compilation of start-up companies and scientific advances paving the way in emerging biotech markets.
Three months after Biogen Idec Inc. failed to acquire Facet Biotech Corp. for $17.50 per share, Abbott is getting the job done with a $27-per-share offer. (BioWorld Today)
Since nothing stirs the faithful quite so much as the perception of
persecution, the anti-science forces have been freshly energized by
The Lancet's retraction of a controversial 1998 paper suggesting a link between the MMR vaccine and autism. (BioPerspectives)
LONDON – Cellzome Ltd. signed its second big deal with GlaxoSmithKline plc, agreeing on a €475 million (US$644.3 million) collaboration to apply its epigenetics platform technology in the discovery of oral small-molecule drugs for treating immuno-inflammatory diseases. (BioWorld International)
